Background
==========

The correct functioning of the p53-MDM2-p14^ARF^ pathway requires a delicate balance between the opposing effects of its different components \[[@B1]-[@B3]\]. Genetic and epigenetic alterations have been shown to distort this balance in various human malignancies, allowing tumor cells to over-ride the tumor suppressor activity of the p53 protein, thereby facilitating neoplastic conversion \[[@B4]\]. In the vast majority of human neoplasia, including colorectal cancer (CRC), deregulation of the p53 pathway usually occurs by direct inactivation of the *TP53* gene itself; this occurs mainly via point mutations \[[@B5]\], which usually increase the stability of the mutant p53 protein, leading to its overexpression \[[@B6]\]. However, a significant proportion of CRCs, which include mainly microsatellite instability-high (MSI-H) CRCs, and a subset of microsatellite-stable (MSS) sporadic CRCs, display a particular immunohistochemical p53 expression pattern characterized by an accumulation of p53 protein restricted to a limited number of tumor cells, a profile that we previously termed 'restricted p53 overexpression' \[[@B7]\]. This CRC subgroup has an extremely low frequency of *TP53* mutation, and displays overexpression of MDM2 and normal expression of p21, suggesting that deregulation of p53 pathway in this CRC subgroup may be due to other alternative mechanisms than *TP53* mutation.

Inactivation of the *p14*^*ARF*^ gene has been proposed as a mechanism that is functionally equivalent to an inactivating *p53* mutation, in that it disrupts p53 activity in tumors retaining the wild-type *TP53* gene \[[@B4]\], and more particularly in sporadic MSI-H CRC \[[@B8],[@B9]\]. In this study, we examined whether *p14*^ARF^ inactivation could be one of the mechanisms disturbing the p53 pathway in CRCs, particularly in tumors displaying a restricted p53 overexpression pattern. Therefore, we conducted detailed genetics and epigenetics analysis of the *p14*^ARF^ gene in CRC tumors for which we had complete data on MSI status and DNA mismatch repair deficiency or sufficiency, and we investigated the relationships between *p14*^ARF^ alterations and MSI phenotype, between *p14*^ARF^ alterations and the p53 protein expression pattern and its mutational status, as well as with MDM2 protein expression.

Results
=======

*p14*^ARF^ gene alterations in colorectal cancer
------------------------------------------------

In our sample, we found that *p14*^*ARF*^ mutations were extremely rare; we detected only a previously reported point mutation in one sample (1/98; 1%). This somatic missense mutation was detected in exon 2 and corresponds to a C→T transition on a CpG dinucleotide site, affecting the codon 121 (p.Ala121Val) for the *p14*^*ARF*^ gene, and the codon 107 (p.Arg107Cys) for the *p16/CDKN2A* gene. Of the ninety-six patients, five (5%) patients, including two of the five patients with Lynch syndrome (hereditary non-polyposis colorectal cancer (HNPCC); OMIM \#120435) were carriers of a polymorphic variant corresponding to a substitution of G→A in codon 148 in exon 2 (p.Ala148Thr) affecting only the *p16/CDKN2A* open-reading frame. Gene dosage detected no copy-number changes in any of the 98 CRCs examined.

*p14*^ARF^ promoter methylation in tumors and adjacent colon mucosa from patients with colorectal cancer
--------------------------------------------------------------------------------------------------------

Overall, MSP analysis within the 5′ CpG island of *p14*/ARF flanking exon 1β identified coexistence of methylated and unmethylated alleles in tumors and matched adjacent normal-appearing colon mucosa in 91 of the 98 patients (Figure [1](#F1){ref-type="fig"} A). By contrast, a distinct methylation profile indicating heavy methylation was seen in seven of the ninety-eight (7.1%) CRCs examined. In these tumors, MSP results identified only methylated alleles in tumors, whereas matched adjacent normal colon mucosa contained both methylated and unmethylated PCR products (Figure [1](#F1){ref-type="fig"} B).

![**Methylation of the*p14***^**ARF**^**promoter in tumors and normal colon mucosa from patients with colorectal cancer** (**A**) ***p14***^**ARF**^**promoter methylation analysis by methylation-specific PCR revealed coexistence of both unmethylated (U) and methylated (M) PCR products in tumor (T) and adjacent colon mucosa (N).** (**B**) Extensive methylation of *p14*^ARF^ promoter in tumors. The methylated PCR product was predominantly detected in tumor, whereas the adjacent colon mucosa produced both the unmethylated and methylated PCR products. MW, standard molecular weight, control +, positive control for methylated allele, (bisulfite-modified genomic blood DNA pretreated with the CpG methylase (M.SssI)); H~2~O, negative control with water only.](1868-7083-4-9-1){#F1}

Evaluation of density of *p14*^ARF^ promoter methylation in tumors and normal colon mucosa from patients with colorectal cancer
-------------------------------------------------------------------------------------------------------------------------------

Next, we evaluated the degree of *p14*^ARF^ promoter methylation, limiting the analysis to tumors and corresponding adjacent colon mucosa from 35 randomly selected patients (Table [1](#T1){ref-type="table"}), including one of the seven CRCs that was identified as having heavy methylation by MSP (sample T2, Table [1](#T1){ref-type="table"}).

###### 

Clinicopathological and molecular data for patients analyzed by bisulfite genomic sequencing

  **Patient's number**   **Location**   **Type of differentiation**   **Stage**   **MMR IHC**    **MSI status**   **p53 IHC**   ***TP53*mutation**
  ---------------------- -------------- ----------------------------- ----------- -------------- ---------------- ------------- ----------------------
  1                      Sigmoid        Moderate                      IV          Positive       MSS              D             p.R248W
  3                      Sigmoid        Moderate                      IIIB        Positive       MSS              D             No
  11                     Left           Moderate                      IV          Positive1      MSI-H            D             No
  12                     Rectum         Moderate                      IIA         Positive       MSS              D             p.R273C
  15                     Sigmoid        Well                          IV          Positive       MSS              D             p.R248Q
  24                     Left           Moderate                      IIA         Positive       MSS              D             No
  26                     Rectum         Well                          I           Positive       MSS              D             p.R248W
  28                     Rectum         Moderate                      IV          Positive       MSS              D             No
  30                     Sigmoid        Poor                          IIIB        Positive       MSS              D             p.C135R
  33                     Rectum         Well                          IIA         Positive       MSS              D             No
  34                     Left           Well                          IIB         Positive       MSS              D             No
  35                     Right          Well                          IIA         Positive       MSS              D             p.\[R158H (+)R267Q\]
  17                     Sigmoid        Well                          I           Positive       MSS              D             p.R248Q
  2                      Right          Well                          IIA         MLH1-/PMS2-†   MSI-H            R             No
  4                      Right          Mucinous                      IIIC        MLH1-/PMS2-‡   MSI-H            R             No
  5                      Left           Mucinous                      IIA         MLH1-/PMS2-‡   MSI-H            R             No
  6                      Right          Well                          IIA         MSH2-/MSH6-†   MSI-H            R             No
  7                      Right          Poor                          IIA         MLH-/PMS2-‡    MSI-H            R             No
  8                      Left           Poor                          IV          Positive       MSS              R             No
  9                      Right          Mucinous                      IIIB        Positive       MSS              R             No
  10                     Right          Mucinous                      IIIB        MLH1-/PMS2-†   MSI-H            R             No
  13                     Left           Well                          IIA         Positive       MSS              R             No
  14                     Left           Well                          IV          Positive       MSS              R             No
  16                     Sigmoid        Mucinous                      IIA         Positive       MSS              R             No
  18                     Rectum         Poor                          IIIC        MLH1-/PMS2-‡   MSI-H            R             No
  19                     Left           Well                          I           MLH1-/PMS2-†   MSI-H            R             No
  22                     Right          Mucinous                      IIIB        MLH1-/PMS2-‡   MSI-H            R             No
  23                     Right          Poor                          IIA         MLH1-/PMS2-1   MSI-H            R             No
  25                     Left           Mucinous                      IIA         Positive       MSS              R             No
  29                     Left           Moderate                      IIA         Positive       MSS              R             No
  20                     Rectum         Moderate                      IIA         Positive       MSS              N             No
  21                     Rectum         Mucinous                      IIB         Positive       MSS              N             p.\[K291X(+) H297Y\]
  27                     Rectum         Moderate                      IIA         Positive       MSS              N             c.672 + 1 G→A
  31                     Right          Moderate                      IIIC        Positive       MSS              N             p.Q165X
  32                     Rectum         Moderate                      IIIC        Positive       MSS              N             No

Abbreviations: MMR, DNA mismatch repair system; MSI, microsatellite instability; MSI-H, microsatellite instability-high; MSS, microsatellite-stable; IHC, immunohistochemistry; D, diffuse pattern of p53 expression, R, restricted pattern of p53 expression, N, negative pattern of p53 expression.

\*MMR deficiency with unknown origin.

†Lynch syndrome.

‡Sporadic MSI-H colorectal cancer with activating V600E *BRAF* somatic mutation, indicating *MLH1* epigenetic silencing.

Using BGS, we analyzed methylation within the 5′ CpG island of *p14*^ARF^ flanking exon 1β, targeting a region containing 27 individual CpG sites, including all the CpG sites analyzed by MSP in this region (see Additional file 1: [Figure S1](#S1){ref-type="supplementary-material"}). BGS showed different *p14*^ARF^ promoter methylation levels among the 35 tumors and adjacent colon mucosa tested, with the highest methylation levels recorded in tumor samples (Figure [2](#F2){ref-type="fig"}, Figure [3](#F3){ref-type="fig"}). Of the 35 tumors examined, the range of fully methylated CpG was 0 to 25 and the median was 9 (95% CI 1 to 13), whereas in paired normal colon mucosa the range was 0 to 17 and the median 0 (95% CI 0 to 2) (*P* = 0.004). Of the thirty-five tumors, eighteen (51%) were extensively methylated (\>9/27 CpG sites methylated, median of fully methylated CpG sites), six (17%) were partially methylated (\>3/27 CpG sites partially methylated, median of partially methylated CpG sites), and 11 (32%) were unmethylated (Table [2](#T2){ref-type="table"}).

![**Heterogeneity of*p14***^**ARF**^**promoter methylation in colorectal tumors.** The samples analyzed are represented on the horizontal line, and the 27 CpG sites on the vertical line. For each case, the methylation status of each individual CpG site is shown: an empty block indicates that the concerned CpG site is unmethylated, a black block indicates that the concerned CpG sites is fully methylated, and a gray block indicates that the concerned CpG site is partially methylated.](1868-7083-4-9-2){#F2}

![***p14***^**ARF**^**promoter methylation in adjacent colon mucosa.**](1868-7083-4-9-3){#F3}

###### 

**Relationships between*p14***^**ARF**^**promoter methylation and clinicopathological data, p53 and MDM2 protein expression,*TP53*mutational status, and microsatellite instability phenotype**

  **Clinicopathological and molecular parameters**   **Overall (%)**   ***p14*ARF promoter methylation profile**                
  -------------------------------------------------- ----------------- ------------------------------------------- ------------ -----------
  Age, years, mean ± SD                                                64 ± 12                                     69 ± 10      0.2057^1^
  Gender                                                                                                                        
   Male                                              16 (46%)          5 (45.5%)                                   11 (45.8%)   0.9833
   Female                                            19 (54%)          6 (54.5%)                                   13 (54.2%)   
  Type of tissue                                                                                                                 
   Tumor                                             35                11 (31%)                                    24 (69%)     0.0019
   Adjacent colon mucosa                             35                24 (69%)                                    11 (31%)     
  Tumor location                                                                                                                
   Right side                                        10 (29%)          3 (27.3%)                                   7 (29.2%)    \>0.05
   Left side                                         25 (71%)          8 (72.7%)                                   17 (70.8%)    
  Differentiation                                                                                                               
   Well or moderate                                  22 (62.9%)        10 (90.9%)                                  12 (50%)     0.0270
   Poor or mucinous                                  13 (37.1%)        1 (9.1%)                                    12 (50%)      
  Clinical stage                                                                                                                
   Stage I                                           3 (8.6%)          \-                                          3 (12.5%)    0.4674^2^
   Stage II                                          17 (48.6%)        5 (45.4%)                                   12 (50%)      
   Stage III                                         9 (25.7%)         3 (27.3%)                                   6 (25%)       
   Stage IV                                          6 (17.1%)         3 (27.3%)                                   3 (12.5%)     
  p53 immunohistochemistry                                                                                                      
   Negative pattern                                  5 (14.3%)         3 (27.3%)                                   2 (8.3%)     0.0275^2^
   Diffuse pattern                                   13 (37.1%)        6 (54.5%)                                   7 (29.2%)     
   Restricted overexpression                         17 (48.6%)        2 (18.2%)                                   15 (62.5%)    
  MDM2 immunohistochemistry                                                                                                     
   Negative                                          12 (34.3%)        7 (63.6%)                                   5 (20.8%)    0.0223
   Overexpression                                    23 (65.7%)        4 (36.4%)                                   19 (79.2%)    
  p21 immunohistochemistry                                                                                                      
   Loss to mild                                      9 (25.7%)         6 (54.5)                                    3 (12.5%)    0.0146^2^
   Moderate to high                                  26 (74.3%)        5 (45.5)                                    21 (87.5%)    
  *TP53* mutational status                                                                                                      
   Mutation present                                  10 (28.6%)        5 (45.5%)                                   5 (20.8%)    0.2266
   No mutation detected                              25 (71.4%)        6 (54.5%)                                   19 (79.2%)    
  MSI status                                                                                                                    
   MSI-H                                             11 (31.4%)        1 (9.1%)                                    10 (41.7%)   0.0539
   MSS                                               24 (68.6%)        10 (90.9%)                                  14 (58.3%)    

Abbreviations: MSI, Microsatellite instability, MSI-H, microsatellite instability-high; MSS, microsatellite-stable.

^2^Two-sided two-sample *t*-test.

^2^Two-tailed Fisher's exact test.

Although the majority of normal colon mucosa tested (69%) showed a significantly low frequency of methylation compared with matched tumor samples (*P* = 0.0019) (Table [2](#T2){ref-type="table"}), extensive methylation was detected in the normal colon mucosa from six patients, including a patient with Lynch syndrome (N7; Figure [3](#F3){ref-type="fig"}) with a germline mutation in the *MLH1* gene (Table [1](#T1){ref-type="table"}) and five patients with sporadic CRC: two MSS tumors (N1, N29; Figure [3](#F3){ref-type="fig"}) and three MSI-H tumors (N4, N5, N22; Figure [3](#F3){ref-type="fig"}) with activating V600E *BRAF* somatic mutation associated with *MLH1* epigenetic silencing (Table [1](#T1){ref-type="table"}).

Correlation between *p14*^ARF^ promoter methylation, clinicopathological features, p53 pathway alterations, and microsatellite instability status in colorectal cancer
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Further, we compared *p14*^ARF^ methylation data from the 35 randomly selected patients analyzed by BGS with their clinicopathological features and the molecular changes in their tumors. No significant association was seen between *p14*^ARF^ methylation and either age or gender (Table [2](#T2){ref-type="table"}). Although the majority of right-sided colon tumors (7/10) had increased *p14*^ARF^ methylation, no significant association between *p14*^ARF^ methylation and tumor location was seen (Table [2](#T2){ref-type="table"}). Correlation analysis identified a significant association between *p14*^ARF^ hypermethylation and poorly differentiated or mucinous tumors (*P* = 0.0270) (Table [2](#T2){ref-type="table"}), but no significant association between *p14*^ARF^ methylation and clinical stage was seen (Table [2](#T2){ref-type="table"}). Compared with tumors exhibiting negative and diffuse patterns of p53 protein immunohistochemical expression, the tumors displaying a restricted p53 overexpression profile (15/17) showed a significant increase in *p14*^ARF^ methylation (*P* = 0.0274) (Table [2](#T2){ref-type="table"}). *p14*^ARF^ methylation was also significantly associated with MDM2 overexpression (*P =* 0.0223) (Table [2](#T2){ref-type="table"}). Most tumors exhibiting *p14*^ARF^ hypermethylation showed an absence of *TP53* mutation (19/24; 79%), but no significant association between *p14*^ARF^ promoter methylation and *TP53* mutational status was seen (Table [2](#T2){ref-type="table"}). MSI-H CRCs were more frequently hypermethylated than MSI-low (MSI-L)/MSS CRCs (*P* = 0.0539) (Table [2](#T2){ref-type="table"}). However, after stratification by p53 immunohistochemical expression pattern, the relationship between MSI status and *p14*^ARF^ methylation was no longer significant (Figure [4](#F4){ref-type="fig"}).

![**Relationship between*p14***^**ARF**^**promoter methylation and microsatellite instability (MSI) status.** The MSI-high (MSI-H) tumors had an overall higher frequency of *p14*^ARF^ promoter methylation compared with MSS tumors, but after stratification by restricted p53 overexpression, the relationship between *p14*^ARF^ methylation and MSI status was no longer significant.](1868-7083-4-9-4){#F4}

Quantification and distribution of *p14*^ARF^ promoter methylation in tumors and normal colon mucosa from patients with colorectal cancer
-----------------------------------------------------------------------------------------------------------------------------------------

We evaluated the density and the distribution of methylation within the 5′ CpG island of the *p14*^ARF^ promoter region and exon 1β. Using bisulfite genomic cloning and direct sequencing, we analyzed 200 clones obtained from 10 tumors and matched adjacent colon mucosa. For each clone, the methylation status of each individual CpG site was determined (Figure [5](#F5){ref-type="fig"}). For all 27 CpG sites evaluated, we found a significantly (*P* \<0.0001) increased number of methylated clones in tumors (median 38%; 95% CI 25 to 41%; range 13 to 47%) compared with the adjacent normal colon mucosa (median 9%; 95% CI 5 to 13%; range 1 to 24%) (Table [3](#T3){ref-type="table"}). Although most normal colon mucosa (7/10) showed only sparse methylation (Figure [5](#F5){ref-type="fig"}), densely methylated clones were seen in three of the ten normal colon mucosa tested (N1, N18 and N29; Figure [5](#F5){ref-type="fig"}). Bisulfite genomic cloning and direct sequencing also showed that methylation involving both CpG sites within the proximal and the distal region of the 5′ UTR CpG island of the *p14*^ARF^ flanking exon 1β (nucleotide position −69 to position +4 relative to the translation codon ATG) is not a frequent event in CRC, but seems to occur more particularly in tumors displaying a restricted pattern of p53 overexpression, including MSI-H and MSS tumors (Figure [5](#F5){ref-type="fig"}). Overall, the 3′ region of exon 1β was more densely methylated (median 41%; 95% CI 38 to 43%; range 27 to 47%) than the promoter and 5′ region of exon 1β (median 22%; 95% CI 17 to 25%; range 13 to 25%) (*P* = 0.0001) (Table [3](#T3){ref-type="table"}). However, the number of methylated clones on CpG sites within the proximal region of the 5′ CpG island of *p14*^ARF^ was significantly higher in tumors displaying a restricted pattern of p53 overexpression (median 30%; 95% CI 24 to 36%; range 17 to 36%) than in tumors exhibiting a strong diffuse p53 expression pattern (median 0%; 95% CI 0 to 3%; range 0 to 3%) (*P* = 0.0003) (Table [3](#T3){ref-type="table"}).

![**Density and distribution of methylated CpG within the 5′ CpG island of*p14***^**ARF**^**flanking exon 1β.** Depicted is the distribution of methylated CpG in tumors (up) and corresponding adjacent colon mucosa (down) from 10 patients. For each case, 10 independent clones (represented on horizontal line (a) to (j) were examined. The circles on the vertical line represent the 27 CpG (CpG 1 to 27) sites analyzed for each individual clone. Note that the translation start site is located between CpG sites 8 and 9. An empty circle indicates that the concerned CpG site is unmethylated, a black circle indicates that the concerned CpG site is methylated. For each tumor, the microsatellite instability (MSI) status and p53 immunohistochemistry are indicated. MSI-H, microsatellite instability-high; MSS, microsatellite-stable; p53 D, diffuse pattern of p53 expression, p53 R, restricted pattern of p53 overexpression.](1868-7083-4-9-5){#F5}

###### 

**Distribution and density of*p14***^**ARF**^**methylation in tumors and adjacent colon mucosa from patients with colorectal cancer**

  **CpG site**   **Position relative to ATG**   **% of methylated clones within the 5′ CpG island flanking exon 1β**             
  -------------- ------------------------------ ---------------------------------------------------------------------- ---- ---- ----
  1              −69                            13                                                                     5    3    17
  2              −43                            17                                                                     1    0    24
  3              −40                            22                                                                     1    0    31
  4              −35                            25                                                                     4    0    36
  5              −28                            22                                                                     2    0    31
  6              −22                            19                                                                     2    0    27
  7              −10                            22                                                                     5    3    30
  8              −7                             21                                                                     3    0    30
  9              +4                             30                                                                     5    3    41
  10             +25                            41                                                                     8    37   43
  11             +31                            42                                                                     12   43   41
  12             +34                            45                                                                     12   50   43
  13             +36                            43                                                                     18   43   43
  14             +38                            34                                                                     12   33   34
  15             +42                            43                                                                     13   43   43
  16             +47                            41                                                                     15   53   36
  17             +50                            45                                                                     9    50   43
  18             +52                            43                                                                     12   57   37
  19             +66                            47                                                                     9    50   46
  20             +80                            44                                                                     9    50   41
  21             +82                            40                                                                     13   37   41
  22             +90                            38                                                                     13   27   43
  23             +105                           38                                                                     13   47   34
  24             +114                           41                                                                     19   50   37
  25             +118                           34                                                                     17   37   33
  26             +121                           31                                                                     24   37   29
  27             +133                           27                                                                     9    13   33

The percentage of methylated clones was calculated in all tumors (n = 10, ≥10 clones analyzed for each tumor) and adjacent normal colon mucosa (n = 10, ≥ 10 clones analyzed for each sample) for every CpG site. The percentage of methylated clones was higher in tumors median 38%, 95% CI 25-41%; range 13-47%), than in normal colon mucosa (median 9%, 95% CI 1 to 24; range 1 to 24%) (Wilcoxon rank sum test, *P* \<0.0001). The percentage of methylated clones on proximal CpG sites was also higher in tumors with a restricted p53 overexpression pattern (median 30%, 95% CI 24 to 36%, range 17 to 36%) than in tumors with a diffuse p53 overexpression pattern (median 0%, 95% CI 0 to 3%, range 0 to 3%) (Wilcoxon rank sum test, *P* = 0.0003).

Discussion
==========

The purpose of this study was to investigate whether alteration of *p14*^ARF^, a key regulator of p53-MDM2 interaction, plays a role in deregulating the p53 pathway in a subgroup of CRCs exhibiting a restricted pattern of p53 overexpression significantly associated with MSI-H phenotype, low *TP53* mutation, and MDM2 overexpression, and inversely correlated with p21 expression loss \[[@B7]\].

Contrary to the usual situation in solid tumor types such as melanoma, pancreatic tumors and some lung tumors \[[@B10]-[@B12]\], the present study confirmed the extremely low frequency of intragenic mutations and allelic losses at the *p14*^ARF^ locus in CRC \[[@B13]\]. Indeed, direct sequencing detected only one (previously reported) missense mutation affecting both the *p14*^ARF^ and *p16*/*CDKN2A* genes \[[@B14]\]. Only 5% percent of the cases, including two patients with Lynch syndrome, were carriers of p.Ala148Thr, a variant considered a non-synonymous single nucleotide polymorphisms (nsSNP, rs3731249) \[[@B14],[@B15]\]. Although the functional significance of this SNP has been controversial in studies of several cancer types \[[@B15]-[@B17]\], its role in CRC risk assessment warrants investigation because this variant occurred at an evolutionarily conserved amino acid with a low intolerance index, as predicted by the Sorting Intolerance from Tolerance (SIFT) program \[[@B18]\].

We evaluated epigenetic changes within the *p14*^ARF^ promoter using two different methylation assays, MSP and BGS. We used MSP because it is widely recognized as a highly sensitive methylation assay, allowing detection of up to 0.01% of methylated alleles of a given CpG island \[[@B19]\]. However, this method provides only qualitative data, so for quantitative analysis, BGS complemented by cloning and direct sequencing, was used \[[@B20]-[@B22]\]. Although BGS is a high-resolution assay, this technique is less sensitive than MSP as detection requires at least 25% of the alleles to be methylated \[[@B22]\], suggesting a risk of disagreement between the two methods.

One of our main findings was the detection of *p14*^ARF^ promoter silencing as a potential cause of deregulation of the p53-MDM2-p14^ARF^ signaling axis in a specific subgroup of CRCs. Using BGS, we fully characterized 35 of the 98 CRCs analyzed. A significant increase in *p14*^ARF^ promoter methylation was evident in 24 CRCs (69%), and interestingly, 63% of the cases (15/24) were tumors exhibiting the restricted pattern of p53 overexpression (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

The *p14*^ARF^ promoter has been previously reported to be preferentially hypermethylated in CRCs retaining the wild-type *TP53* gene \[[@B8],[@B13],[@B23]\], and has been particularly associated with sporadic MSI-H CRCs associated with *MLH1* epigenetic silencing \[[@B8],[@B9]\]. In addition to the relationship between the restricted p53 overexpression pattern and the MSI-H phenotype \[[@B7]\], we found that *p14*^ARF^ promoter methylation was increased in CRCs with restricted p53 overexpression, irrespective of MSI status (Figure [4](#F4){ref-type="fig"}). This observation, along with our previous findings, shows that regardless of the MSI status, CRCs with the restricted p53 overexpression pattern exhibit a significant overlap in terms of their pathobiology, supporting the hypothesis of a common tumorigenic event \[[@B7]\]. In agreement with these observations, previous studies have shown that although CRCs have been reported to evolve either through the classic chromosomal instability pathway or through the alternative MSI pathway known to be significantly associated with the CpG island methylator phenotype, the mechanisms underlying these genomic instability pathways are not always independent \[[@B24],[@B25]\], and a significant degree of overlap can therefore be expected in some tumors, regardless of the MSI status.

Even though a high frequency of *p14*^ARF^ promoter methylation has been previously reported to occur in tumors without *TP53* mutations \[[@B8],[@B13],[@B23],[@B26]\], an inverse correlation between *TP53* mutations and epigenetic inactivation of *p14*^ARF^ in CRCs does not always hold true \[[@B27]\]. In the current study, we found that although the majority of heavily methylated tumors did not have a *TP53* mutation, *p14*^ARF^ promoter methylation was increased in almost half of tumors (5/10) carrying *TP53* mutations (Table [2](#T2){ref-type="table"}). Interestingly, the most exceptional feature of these tumors was the distribution of *p14*^ARF^ methylation. Using bisulfite genomic cloning and direct sequencing, we found that extensive methylation involving both the proximal and the distal CpG sites within the 5′ CpG island of *p14*^ARF^ flanking exon 1β was rare in CRC generally, but occurred more frequently in CRCs displaying a restricted pattern of p53 overexpression (Table [3](#T3){ref-type="table"}). In tumors showing a strong diffuse p53 expression pattern associated with missense *TP53* mutations, the majority of the methylated clones exhibited partial methylation involving CpG sites downstream from the translation start site and extending throughout exon 1β (Figure [5](#F5){ref-type="fig"}, Table [3](#T3){ref-type="table"}). This pattern of methylation was also seen in some normal colon mucosa (Figure [3](#F3){ref-type="fig"}; Figure [5](#F5){ref-type="fig"} (N29)). Our results support previous observations by Zheng *et al*., who showed that partial methylation is the most common pattern of *p14*^ARF^ methylation in primary sporadic CRCs \[[@B28]\].

Owing to the limited availability of an efficient antibody raised against the p14^ARF^ protein, we were unable to examine p14^ARF^ expression by immunohistochemistry in our tumor samples. However, previous experiments, mainly performed in CRC cell lines, have shown that extensive methylation of CpG sites within the 5′ CpG island and exon 1β of *p14*^ARF^ is associated with transcription silencing and correlates with extremely low levels of *p14*^ARF^ mRNA, whereas partial methylation correlates with intermediate mRNA expression \[[@B28],[@B29]\]. Based on these findings, we suggest that the extensive methylation seen in CRCs with restricted p53 overexpression may represent an important functional defect in the *p14*^ARF^ gene, but additional studies are needed to verify this hypothesis.

Additionally, a significant relationship between MDM2 overexpression and increased *p14*^ARF^ methylation was seen (79%; *P* = 0.0223). It is known that tumors with reduced *p14*^ARF^ activity have higher MDM2 activity, which potentially leads to p53 inactivation \[[@B30]\]. Moreover, using immunohistochemistry, a strong inverse relationship between MDM2 and *p14*^ARF^ inactivation has been previously found in different tumor types, including a subtype of human lung carcinoma displaying an abnormally stabilized p53 protein \[[@B31]\]. Therefore, it is conceivable that the increased MDM2 expression seen in CRCs with restricted p53 overexpression may reflect cellular functional consequences of *p14*^ARF^ epigenetic inactivation. Interestingly, a previous study found an association between *p14*^ARF^ epigenetic silencing and an abnormal cytoplasmic localization of MDM2 in primary CRC and tumor cell lines, mainly explained as a direct consequence of *p14*^ARF^ loss of function \[[@B32]\]. In the current study, we did not find any MDM2 subcellular localization in our cohort of 98 CRCs. Functional interpretation of MDM2 immunostaining data are complicated by the existence of several isoforms, of which detection depends on the antibody used, and this may explain these discrepancies.

It is widely believed that CpG islands in autosomal genes are usually unmethylated, except when associated with certain imprinted genes and with genes that undergo X-chromosome inactivation in females \[[@B33],[@B34]\]. Supporting this paradigm, initial studies indicated methylation of the 5′ CpG island of the *p14*^ARF^ promoter exclusively in tumor cells \[[@B13],[@B27]\]. However, this view was challenged by detection of *p14*^ARF^ methylation in normal colon mucosa from patients with CRC and from healthy people without clinical evidence of colon cancer \[[@B8],[@B35],[@B36]\]. In the current study, using the MSP assay, we found coexistence of unmethylated and methylated alleles in the majority of tumors and in all adjacent normal colon mucosa. A clear difference in methylation pattern between tumor and adjacent normal colon mucosa was seen only in the seven tumors (7.1%) that showed heavy methylation. The sensitivity of our MSP assay was significantly high. However, given that we used the conventional MSP assay, which provides qualitative data, we were limited by this high sensitivity, and were unable to distinguish the *p14*^ARF^ methylation occurring in a small proportion of cells from the high-level methylation associated with epigenetic inactivation. Using the BGS approach, we found that the level of *p14*^ARF^ methylation in normal tissues was generally below the threshold detection of the BGS assay, and was significantly increased in tumors compared with normal colon mucosa. However, hypermethylation was still present in normal colon mucosa from some patients, and more frequently in those with DNA mismatch repair deficiency associated with *MLH1* gene inactivation. Indeed, hypermethylation of the 5′ CpG islands of the *p14*^ARF^ and *MLH1* genes in normal-appearing mucosa surrounding colorectal neoplastic lesions has been described as a 'field cancerization' phenomenon, which may occur before genetic alterations in the early stages of carcinogenesis \[[@B37]\].

Conclusion
==========

In summary, this study provides evidence that *p14*^ARF^ promoter hypermethylation may represent an important cause of deregulation of the p53-MDM2-p14^ARF^ signaling axis in a subgroup of CRCs displaying a restricted overexpression pattern of the p53 protein, associated with the wild-type *TP53* gene, concomitant MDM2 overexpression, and normal p21 expression. Although this subgroup of CRCs includes the majority of MSI-H tumors (namely Lynch syndrome-related CRCs and sporadic MSI-H CRCs), methylation involving both proximal and distal CpG sites within the 5′ CpG island flanking exon 1β of *p14*^ARF^ preferentially occurs in these tumors independently of MSI status. Further investigations are warranted to clarify the significance of this high-level methylation on the transcriptional activity of the *p14*^ARF^ gene. The results from this work could have clinical implications, because therapeutic delivery of small p14^ARF^ peptides has been reported to mimic the growth-inhibitory effects of full-length p14^ARF^ expression and to restore p53 activity in cancers in which MDM2 is overexpressed or p14^ARF^ is functionally inactivated \[[@B38]\]. Evaluation of the clinical relevance of such promising therapeutic measures would essentially provide a new set of more efficient treatment possibilities in patients with CRC who have tumors displaying the restricted pattern of p53 overexpression.

Methods
=======

Ethics approval
---------------

Tissues collection and analyses were approved by the institutional ethics committee of the Catholic University of Louvain (Faculty of Medicine UCL), and all participants provided written informed consent.

Patients
--------

We examined 98 surgical resected tumors and corresponding adjacent normal colon mucosa from the cohort of patients (48 men, 50 women, mean ± SD age 64 ± 14 years) with primary CRC we reported previously \[[@B7]\]. For the 98 CRCs, clinicopathologic data and evaluation of the DNA mismatch repair (MMR) system (using MSI analysis, immunohistochemistry (IHC) for MMR proteins, MMR germline mutation) and somatic *BRAF* mutation, had been performed previously \[[@B7]\], but only data from the 35 patients extensively studied by bisulfite genomic sequencing (BGS) are shown in Table [1](#T1){ref-type="table"}. Immunohistochemical analysis for p53, MDM2, and p21 proteins and mutational analysis for *TP53* were also previously performed. Three distinct patterns of p53 expression were seen, including a restricted p53 overexpression pattern clearly distinguishable from both the negative pattern and the strong diffuse pattern \[[@B7]\]. MDM2 immunohistochemical expression was semi-quantitatively evaluated based on the percentage of positive tumor cells. MDM2 overexpression was recorded if a positive staining was evidenced in more than 10% of tumor cells nuclei \[[@B7]\].

*p14*^ARF^ mutation screening and gene dosage
---------------------------------------------

Sequence-specific primers (according to GenBank accession number NM_058195) for exon 1β and exon 2 (common to both *p16*/CDKN2A and *p14*^ARF^), including the intronic flanking regions of the *p14*^ARF^ gene, were designed using Primer3 software (<http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi>). PCR was carried out for each sample, and PCR products were then purified, sequenced, and run on an automated laser fluorescent DNA sequencer (3130XL; AB Applied Biosystems, Foster City, CA, USA). To detect large rearrangements (allelic imbalances) throughout the *p14*^ARF^ locus, multiplex ligation-dependent probe amplification (MLPA) was performed using (Salsa PO24B 9p21 CDKN2A/2B region kit; MRC-Holland BV, Amsterdam, the Netherlands), in accordance with the manufacturer's instructions. MLPA PCR products were separated by capillary electrophoresis using an automated laser fluorescent DNA sequencer (3130 XL; AB Applied Biosystems, Foster City, CA, USA). The relative quantities of the amplified probes in each sample were determined using Genotyper (Applied Biosystems, Foster City, CA, USA) and Excel (Microsoft Corp., Redmond, WA, USA) software (Gene Marker version 1.5; Softgenetics Inc, State College, PA, USA). The gene dosage quotient was generated using peak height rather than peak area as an indicator of DNA template amount \[[@B39],[@B40]\]. For each sample, a gene dosage quotient score (peak height relative to control) was calculated and adjusted as follows: homozygous loss ≤ 0 to 0.19 ≤ hemizygous loss ≤ 0.7 to 0.75 ≤ wild-type ≤ 1 to 1.3 \< duplication.

Methylation-specific PCR
------------------------

Genomic DNA was extracted from frozen tumors and matched normal tissues using a standard phenol/chloroform method. Thereafter, bisulfite treatment of 300 ng of genomic DNA was performed (Applied Biosystems methylSEQr™ Bisulfite Conversion Kit) in accordance with the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). Methylation-specific PCR (MSP) \[[@B19]\] was performed to examine *p14*^ARF^ promoter methylation within a region located at least −60 base pairs relative to the translation codon, previously reported to be associated with *p14*^ARF^ gene silencing in CRC \[[@B27]\]. Methylation in this region was evaluated using the primer sets previously described \[[@B27]\]. These primers pairs allowed assessment of the methylation status of six CpG dinucleotides specific for the 5′ CpG island of the *p14*^ARF^ gene flanking exon 1β (see Additional file 2: [Table S1](#S2){ref-type="supplementary-material"}). The MSP reactions were carried out in a total volume of 25 μl containing 2.5 μl of the manufacturer's 10× PCR buffer (Roche Diagnostics, Basel, Switzerland), 1.5 μl of 25 mmol/l MgCl~2~, and 0.25 μl of 100 μmol/l dNTPs (dATPs, dTTPs, dCTPs and dGTPs), 1 μl of primer (10 pmol/μl for each), 1 to 1.25 U of DNA polymerase (FastStart; Roche Diagnostics, Basel, Switzerland), and 1 μl of bisulfite-modified genomic DNA. Normal human leukocyte DNA was methylated in vitro with a CpG methylase (M.SssI; New England BioLabs, Beverly, MA, USA) in accordance with the manufacturer's instructions, and used as the MSP methylated-allele positive control. After amplification, 5 μl of PCR products were run in an 8% non-denaturing acrylamide gel with an appropriate size marker. Amplicons were visualized by ethidium bromide staining under UV illumination.

Bisulfite genomic sequencing
----------------------------

BGS primers designed to recognize both methylated and unmethylated alleles were generated based on the human contig sequence (GenBank accession number L41934) using MethPrimer software (<http://www.urogene.org/methprimer/index1.html>) \[[@B41]\]. The designed BGS primers were located within the 5′ CpG island of the *p14*^ARF^ region flanking exon 1β, and were used to amplify a DNA sequence containing 27 CpG sites, including all the CpG sites targeted by the MSP primers within this region (see Additional file 1: [Figure S1](#S1){ref-type="supplementary-material"}). Bisulfite-converted DNA samples from tumor tissue and corresponding adjacent normal tissues from 35 patients, randomly selected from our cohort of patients (Table [1](#T1){ref-type="table"}), were subjected to PCR amplification using primer pair A and B (forward and reverse, respectively), followed by a nested PCR amplification with primer pair C and D (forward and reverse; Additional file 1: [Figure S1](#S1){ref-type="supplementary-material"}). All the primer sequences used are summarized in (Additional file 2: [Table S1](#S2){ref-type="supplementary-material"}). After PCR amplification, the BGS products were purified (Qiaquick PCR Purification Kit; Qiagen Inc., Valencia, CA, USA), and directly sequenced in both directions using primers C and D (forward and reverse; see Additional file 1: [Figure S1](#S1){ref-type="supplementary-material"}) with a commercial kit (Big Dye Terminator Cycle Sequencing Ready Reaction Kit, version 1.3; Perkin Elmer/Applied Biosystems, Foster City, CA, USA) in accordance with the manufacturer's instructions. Sequencing reaction products were purified on filter plates for high-throughput separation (Multiscreen™; Millipore Corp., Bedford, MA, USA) using dextran gel beads (Sephadex^TM^ G-50 Fine Beads; GE Healthcare Bio-Sciences AB, Uppsala, Sweden) in accordance with the manufacturer's instructions. After purification, sequencing reaction products were run on an automated laser fluorescent DNA sequencer (3130XL; AB Applied Biosystems, Foster City, CA, USA). Results were analyzed using the sequencing analysis software for the sequencer (Version 1.5; AB Applied Biosystems, Foster City, CA, USA).

For all 35 patients examined, the bisulfite sequencing chromatogram was analyzed for each individual CpG site, and a specific pattern was assigned: 1) unmethylated, in which the CpG site was fully converted into thymidine, indicating that the concerned CpG site is unmethylated on both alleles (see Additional file 3: [Figure S2](#S3){ref-type="supplementary-material"}), 2) partial, showing an overlap of both thymidine and cytosine peaks on a sequencing chromatogram, indicating the presence of both methylated and unmethylated alleles (see Additional file 3: [Figure S2](#S3){ref-type="supplementary-material"} A), 3) methylated, in which the CpG site was fully methylated, indicating that the concerned CpG site is extensively methylated on both alleles (see Additional file 3: [Figure S2](#S3){ref-type="supplementary-material"} B).

Cloning and sequencing
----------------------

For 10 patients, the amplified bisulfite PCR products from tumor and corresponding normal colon tissues were purified (Qiaquick PCR Purification Kit; Qiagen) and ligated into a pTZ57R/T plasmid vector using a TA cloning and bacterial transformation system (Ins TAclone™ PCR Cloning Kit). The plasmid was inserted into Escherichia coli cells, which were cultured overnight, then recombinant plasmid DNA was isolated and purified (Rapid Miniprep Plasmid Purification System; Marligen Bioscience, Ijamsville, Maryland, USA). Purified plasmid recombinant DNA was subjected to direct PCR amplification in a 25 μl reaction mixture containing 2.5 μl of the manufacturer's 10× PCR buffer (Roche Diagnostics, Basel, Switzerland), 1.5 μl of 25 mmol/l MgCl~2~, and 0.25 μl of 100 μmol/l dNTPs, 1 μl of M13 forward and reverse primer (10 pmol/μl for each), 1 U of DNA polymerase (FastStart; Roche Diagnostics, Basel, Switzerland), and 1 μl of purified recombinant plasmid DNA template. Direct sequencing was performed in both directions using M13 primers with a commercial kit (Big Dye Terminator Cycle Sequencing Ready Reaction Kit, version 1.3; Perkin Elmer/Applied Biosystems, Foster City, CA, USA) in accordance with the manufacturer's instructions. Sequencing reaction products were purified on filter plates for high-throughput separations Multiscreen™; Millipore Corp., Bedford, MA01730 USA) using dextran gel beads (Sephadex^TM^ G-50 Fine Beads; GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and were run on an automated laser fluorescent DNA sequencer (3130XL; AB Applied Biosystems, Foster City, CA, USA). For each sample, at least 10 clones were analyzed. For each clone, the bisulfite genomic sequence was analyzed, and for each individual CpG site a methylation status was assigned.

Statistical analysis
--------------------

We used the Pearson *χ*^2^ test (when the minimum expected value was ≥ 5) or the two-tailed Fisher's exact test (when the minimum expected value was \<5) to compare the frequency of *p14*^ARF^ promoter methylation in 35 patients with CRC in relation to various clinicopathologic parameters and characteristics, including immunohistochemical expression of p53, MDM2, and p21, p53 mutational status and MSI status. Comparison in distribution and density of methylation between tumors and adjacent normal-appearing colon mucosa, and of tumor groups were assessed using the Mann--Whitney or Wilcoxon rank sum test. All statistical analyses were performed using the NCSS 2007 statistical & Power analysis software. All reported P-values were two sided, and the test was significant when the *P* ≤ 0.05.
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###### Additional file 1

**Figure S1*p14***^**ARF**^**promoter methylation analysis by bisulfite genomic sequencing (BGS).** The genomic sequence of 5′CpG island of *p14*^ARF^ region flanking exon 1β was analyzed. The highlighted and numbered CpG indicates the 27 potential CpG sites analyzed. Bold arrows indicate position of forward and reverse MSP primers for methylated (MSPMF/MSPMR) and for unmethylated (MSPUF/MSPUR) alleles. Simple arrows indicate bisulfite genomic sequencing primers specific for both unmethylated and methylated sequences. The putative transcription start site, translation start site (+1), and the end of exon 1β (\*) are indicated.
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###### Additional file 2

**Table S1.** Primer sequences for methylation-specific PCR, bisulfite genomic sequencing, and PCR amplification of exon 1β and exon 2 of the *p14*^*ARF*^ gene.
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###### Additional file 3

**Figure S2.** Bisulfite DNA sequencing chromatograms representing the three different methylation profiles for single CpG dinucleotide sites. (A) DNA sequences from tumor samples showing an overlap of both thymidine and cytosine peaks indicating a partial methylation on CpG site located at position −31 relative to the translation start site (top) compared with another sample showing an unmethylated profile at the same CpG site (bottom), (B) DNA sequences from tumor samples showing full methylation on CpG sites located at +31 and +42 relative to the translation start site (top) compared with another sample showing an unmethylated profile at the same CpG sites (bottom).
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